Screener
Xeris Biopharma Holdings, Inc. XERS Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001867096-26-000065
FAQ
- What is Xeris Biopharma Holdings, Inc.'s cash & equivalents?
- Xeris Biopharma Holdings, Inc. (XERS) reported cash & equivalents of $121.75M in Q2 2026.
- How has Xeris Biopharma Holdings, Inc.'s cash & equivalents changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s cash & equivalents increased by 105.4% year-over-year, from $59.29M to $121.75M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Xeris Biopharma Holdings, Inc.'s cash & equivalents has grown at a 24.2% compound annual growth rate (CAGR), from $37.6M to $111.04M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Xeris Biopharma Holdings, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude